On October 9, GENFLEET-B fell 5.11% in regular trading, trading at 26.74 HKD/share, with Turnover of 18.172 million HKD.

The decline was driven by selling pressure from a recent major shareholder reduction, which was not effectively offset by the company's relatively limited buyback scale. On September 24, Ourea Biotech HK Limited sold 6 million shares at an average price of 27.3 HKD, reducing its long position from 6.34% to 4.64%. Although GENFLEET-B continued repurchasing H shares since September and bought back 135,000 shares on October 8 for approximately 3.8307 million HKD, the cumulative repurchase volume remains relatively small and insufficient to counter the shareholder reduction pressure.

GENFLEET-B is a China-based company focused on innovative drug development for oncology, autoimmune, and inflammatory diseases. Its R&D platform covers target discovery, translational science, clinical development, and key CMC processes.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)